Search Results

Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR) announced today the publication of its clinical validation of a novel drug-specific DRP®-companion diagnostic (CDx) for dovitinib in the peer-reviewed journal PLOS ONE.

The higher the level of a marker of inflammation in circulating blood, the greater the risk of dying from a range of medical disorders, according to a new study published in PLOS ONE.

Jaguar Health, Inc. announced that a dog study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor neratinib has been published in the peer-reviewed journal PLOS ONE.

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high demand for its medicines. Its recently announced Lilly Medicine Foundry—which will support research and development efforts—is just the latest example of the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials.

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell therapy company, the latter of which will inherit the Galapagos name.

GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing cancer therapeutics based on targeting G Protein Coupled Receptors pairs, announces publication of a research paper in PLOS ONE.